Sonic Healthcare share price hits 52-week high: is it a buy?

The Sonic Healthcare Ltd (ASX: SHL) share price has fallen lower this afternoon after reaching a new 52-week high at market open.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sonic Healthcare Ltd (ASX: SHL) share price has fallen lower this afternoon after reaching a new 52-week high at market open.

What happened to the Sonic Healthcare share price?

The Sonic Healthcare share price surged higher at the start of the day to $28.66 per share despite the S&P/ASX 200 (INDEXASX: XJO) index opening lower.

Sonic Healthcare has delivered solid returns for its investors so far this year, with the company's share price climbing 29% since the start of January to outpace the ASX 200 performance over the same period.

The Aussie healthcare sector has been a strong performer this year with many of the top-performing ASX 200 shares comprising the likes of Nanosonics Ltd (ASX: NAN) and InvoCare Limited (ASX: IVC).

Is Sonic Healthcare in the buy zone?

The medical imaging and pathology group has performed strongly so far this year, but what's the catch?

Sonic Healthcare's strong share price performance has been built on a platform of strong earnings, starting with the company's strong half-year results and upgraded full-year guidance in February.

Strong organic growth in Sonic Healthcare's laboratory markets and operations segments saw the company post first-half revenue of $2.9 billion, up 9% 1H 2018.

Sonic also reported a 7% year-on-year (YoY) increase in net profit after tax (NPAT) of $223 million and increased its interim dividend to 33 cents.

Sonic lifted full-year guidance for its earnings before interest, tax, depreciation and amortisation (EBITDA) by 8%, in comparison to EBITDA of $962 million the year prior.

Foolish takeaway

Sonic Healthcare trades at a reasonable price-to-earnings (P/E) ratio of 26.2x earnings, but I still think that's a little on the high side given the ASX 200 average of approximately 17x.

Sonic is a solid dividend stock that currently yields 3% per annum, but I think the company's August full-year results will be the real kicker for investors.

If Sonic Healthcare can post solid earnings growth and deliver on its upgraded guidance and recent acquisition, I'd expect to see the Sonic Healthcare share price push beyond the $30 barrier by the end of August.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended InvoCare Limited and Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »